TNFRSF13B

Across TCGA pan-cancer cohorts, TNFRSF13B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TNFRSF13B data layer compared with 26 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher TNFRSF13B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TNFRSF13B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SCLC, BLCA, and LIHC are the cancer types where TNFRSF13B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →
BLCA	OS	Median	All	0.212	0.720	.007	12	view →
LIHC	DFS	Median	All	0.027	0.556	<.001	12	view →
PRAD	DFS	Median	All	0.166	0.888	<.001	6	view →
SKCM	OS	Median	All	0.835	0.330	.025	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TNFRSF13B–SCLC (OS)

Open the SCLC breakdown →